Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 07.21
    2022

    Addex Completes Reduction in Nominal Value of Shares

  • 06.17
    2022

    Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate

  • 05.27
    2022

    Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

  • 05.19
    2022

    Addex Announces Participation in the H.C. Wainwright Global Investment Conference

  • 05.13
    2022

    Addex Announces Participation in the 22nd Bio€quity Europe Conference

  • 05.10
    2022

    Addex Shareholders Approve All Resolutions at Annual General Meeting

  • 05.05
    2022

    Addex Reports Q1 2022 Financial Results

  • 04.28
    2022

    Addex to Present at the Swiss Biotech Day 2022

  • 04.25
    2022

    Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference

  • 04.13
    2022

    Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics